Gan Lijun

Gan & Lee Pharmaceuticals is a leading Chinese biopharmaceutical company specializing in the development, manufacture, and commercialization of recombinant human insulin and insulin analogs. Founded by Dr. Gan Zhongru, the company was the first in China to develop and produce biosynthetic human insulin and has since expanded its portfolio to include long-acting, fast-acting, and mixed insulin analogs. The company operates large-scale GMP-compliant manufacturing facilities and serves both the domestic Chinese market and international markets through strategic partnerships. Beyond its core insulin business, Gan & Lee is diversifying its pipeline into areas such as oncology, cardiovascular disease, and metabolic disorders.